[144] CG Oncology, Inc. Common stock SEC Filing

Rhea-AI Filing Summary

CG Oncology (CGON) Form 144: The filer notifies a proposed sale of 100,000 shares of common stock through Merrill Lynch on NASDAQ with an approximate sale date of 09/03/2025. The aggregate market value is reported as $2,746,000.00 and the company reports 76,247,581 shares outstanding, implying the filing relates to a transaction representing a known, disclosed portion of outstanding equity.

The securities were acquired on 01/25/2024 in a private placement from the Company and paid in cash the same day. No securities were reported sold by the person in the past three months. The filing includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Positive

• Planned sale disclosed transparently: Form 144 notifies the public of the proposed sale of 100,000 shares.
• Acquisition details provided: Securities were acquired in a private placement on 01/25/2024 and paid in cash the same day.
• Broker and market specified: Broker is Merrill Lynch and the intended exchange is NASDAQ with an approximate sale date of 09/03/2025.

Negative

• None.

Insights

Securities Analyst

TL;DR: A previously private placement holding of 100,000 CGON shares is planned for sale via Merrill Lynch, disclosed under Rule 144.

The filing documents a routine Rule 144 notice: 100,000 shares acquired in a 01/25/2024 private placement are proposed to be sold on 09/03/2025 through Merrill Lynch on NASDAQ with an aggregate market value of $2,746,000. The report states 76,247,581 shares outstanding and no sales in the past three months, consistent with a single-holder sale notification rather than an offering or registration. This is a disclosure event providing transparency about potential share supply entering the market.

Corporate Governance Expert

TL;DR: The Form 144 is a compliance notice documenting an intended sale of shares acquired in a private placement.

The form includes required representations about public disclosure and confirms acquisition details: securities were acquired from the Company in a private placement and fully paid in cash on 01/25/2024. The filer attests to lack of undisclosed material adverse information. The filing contains no information about holder identity or any trading plan dates, and no prior three-month sales are reported.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 555 California Street Suite 1800 San Francisco CA 94104	100000	2746000.00	76247581	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2024	Private Placement	Company			100000	01/25/2024	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CGON Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 100,000 CG Oncology common shares through Merrill Lynch on NASDAQ, with an approximate sale date of 09/03/2025 and an aggregate market value of $2,746,000.00.

When and how were the shares being sold originally acquired?

The shares were acquired on 01/25/2024 in a private placement from the Company and paid for in cash on the same date.

Does the filing report any sales by the same person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

How many shares of CGON are outstanding according to the filing?

The filing reports 76,247,581 shares outstanding.

What representation does the signer make about material information?

The signer represents they do not know any material adverse information regarding the issuer's current or prospective operations that has not been publicly disclosed.